US Broker Ratings

AstraZeneca PLC (AZN) Stock Analysis: Exploring an 8.40% Upside Potential

AstraZeneca PLC (AZN), a titan in the healthcare sector, continues to capture investor attention with its robust portfolio and strategic collaborations. Known for its innovation in drug manufacturing, AstraZeneca is..

Veeva Systems Inc. (VEEV) Stock Analysis: Exploring a 17% Potential Upside in the Booming Health Information Sector

Veeva Systems Inc. (NYSE: VEEV) stands as a formidable player in the health information services industry, offering innovative cloud-based software solutions tailored to the life sciences sector. Headquartered in Pleasanton,..

Novo Nordisk A/S (NVO) Stock Analysis: Is a 13.28% Potential Upside Within Reach?

Novo Nordisk A/S (NYSE: NVO) stands as a titan in the healthcare sector, specifically within the drug manufacturing industry. With a market capitalization of approximately $248.72 billion, this Denmark-based pharmaceutical..

Vertex Pharmaceuticals (VRTX) Investor Outlook: Navigating a Promising 23% Upside Potential

Vertex Pharmaceuticals Incorporated (VRTX), a prominent player in the biotechnology sector, continues to be a company worth watching for investors seeking growth opportunities. With a market capitalization of $100.25 billion,..

AbbVie Inc. (ABBV) Stock Analysis: A Healthcare Giant with Robust 3.12% Dividend Yield and Promising Growth Prospects

AbbVie Inc. (NYSE: ABBV), a formidable player in the healthcare sector, continues to captivate investors with its impressive market position and substantial income potential. With a market capitalization of $371.68..

Danaher Corporation (DHR) Stock Analysis: A 19.50% Upside Potential Beckons Investors

Danaher Corporation (NYSE: DHR), a leading entity in the diagnostics and research industry, is capturing investor attention with its intriguing growth potential and robust market positioning. With a market capitalization..

Edwards Lifesciences (EW) Investor Outlook: Analyzing Potential Upside in the Healthcare Sector

Edwards Lifesciences Corporation (NYSE: EW), a key player in the healthcare sector specializing in medical devices, offers investors a compelling growth narrative amidst the backdrop of an evolving cardiovascular treatment..

Alcon Inc. (ALC) Stock Analysis: Eye-Catching Growth Potential with 22.29% Upside

Alcon Inc. (NYSE: ALC), a stalwart in the healthcare sector, is making waves in the medical instruments and supplies industry with its innovative eye care products. Based in Switzerland, this..

CVS Health Corporation (CVS) Stock Analysis: Strong Buy Ratings and 11.51% Potential Upside

CVS Health Corporation (NYSE: CVS), a stalwart in the healthcare sector, is capturing significant investor attention with its robust market presence and attractive growth prospects. With a market capitalization of..

Johnson & Johnson (JNJ) Stock Analysis: Is the Healthcare Giant a Buy with Its Solid Dividend Yield?

Johnson & Johnson (NYSE: JNJ), a stalwart in the healthcare sector, has long been a favorite among investors for its robust product portfolio and consistent dividend payouts. With a market..

Cel-Sci Corporation (CVM) Stock Analysis: A Biotech with Over 3,000% Potential Upside

Cel-Sci Corporation (CVM) presents an intriguing proposition for investors fascinated by the biotechnology sector. With its focus on leveraging the immune system to combat cancer and other diseases, Cel-Sci operates..

MBX Biosciences, Inc. (MBX) Investor Outlook: Analyst Ratings Suggest 164% Potential Upside

MBX Biosciences, Inc. (NASDAQ: MBX) is capturing investor attention with its promising portfolio of precision peptide therapies and a significant potential upside. With a market capitalization of $479.38 million, this..

Tourmaline Bio, Inc. (TRML) Stock Analysis: Robust Buy Ratings and 144% Potential Upside Highlight Investor Appeal

Tourmaline Bio, Inc. (NASDAQ: TRML) is capturing the attention of investors with its promising position within the biotechnology sector, focusing on developing transformative medicines for immune and inflammatory diseases. Headquartered..

EyePoint Pharmaceuticals, Inc. (EYPT) Stock Analysis: Exploring a Potential 196.70% Upside

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is capturing investor attention with a compelling projection of a 196.70% potential upside. Specializing in developing therapeutics for serious retinal diseases, the company’s innovative approach..

Autolus Therapeutics plc (AUTL) Stock Analysis: Unveiling a 512.88% Potential Upside for Bold Investors

Autolus Therapeutics plc (NASDAQ: AUTL) may not yet be a household name, but this UK-based biotechnology firm is making waves with its cutting-edge approach to T cell therapies aimed at..

Septerna, Inc. (SEPN) Stock Analysis: Biotechnology Innovator with Nearly 100% Upside Potential

Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company headquartered in South San Francisco, California, has captured the attention of investors with its promising pipeline of G protein-coupled receptor (GPCR) oral..

Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Navigating Growth and Challenges in the Medical Device Sector

Treace Medical Concepts, Inc. (NASDAQ: TMCI) is a dynamic player in the healthcare sector, specifically within the medical devices industry. Headquartered in Ponte Vedra, Florida, the company has carved a..

Sage Therapeutics, Inc. (SAGE) Stock Analysis: Navigating Biotech Challenges with a 265.80% Revenue Growth

Sage Therapeutics, Inc. (SAGE), a Cambridge, Massachusetts-based biopharmaceutical company, has recently garnered investor attention due to its impressive 265.80% revenue growth. Specializing in brain health medicines, Sage Therapeutics aims to..

Sionna Therapeutics (SION) Stock Analysis: Evaluating a 49.69% Potential Upside in Biotech Innovation

Sionna Therapeutics, Inc. (NASDAQ: SION) has emerged as a compelling player in the biotechnology sector, with a significant focus on treating cystic fibrosis, a life-altering genetic disorder. Headquartered in Waltham,..

Celcuity Inc. (CELC)

⚠️ No article content returned.

..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds